Ge Long Hui A P P·2025-12-11 10:59Core Viewpoint - The company, Innovent Biologics (688428.SH), has received approval from the National Medical Products Administration for its self-developed next-generation TRK inhibitor, Zolbetuximab (宜诺欣®, ICP-723), making it the first domestically developed next-generation TRK inhibitor approved for marketing in China [1] Group 1 - The new drug is intended for the treatment of adult and adolescent patients aged 12 and older with solid tumors carrying NTRK fusion genes [1] - The development of new drugs is characterized by high technology, high risk, and high added value, with long and complex cycles from research and clinical studies to production [1] - The drug development process is susceptible to uncertainties, which may impact investment decisions [1]